Literature DB >> 15886470

Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.

Albert S Braverman1, Sujatha Rao, Mary Ellen Salvatti, Barbara Adamson, Margaret McManus, Shirley Pierre.   

Abstract

BACKGROUND: Taxanes cause hypersensitivity reactions, averted by premedication with H1 blockers and high glucocorticoid (GC) doses. Prolonged weekly taxane administration may lead to GC toxicity.
PURPOSE: To determine whether patients not hypersensitive to initial paclitaxel (PTX) infusion after high-dose GC premedication will tolerate subsequent, prolonged PTX treatment without GC prophylaxis. PATIENTS AND METHODS: In 115/122 breast cancer patients not hypersensitive to initial PTX treatment, 20 mg dexamethasone (DXM) doses were tapered by 2.0 mg/week, reaching 0 in those receiving 9 or more courses. After 4 PTX courses, diphenhydramine was administered orally, rather than intravenously.
RESULTS: PTX was administered 143 times after 2.0-5.0 mg of DXM and 357 times without DXM. A total of 46 patients received 1-40 PTX courses without DXM. None of these 115 patients experienced hypersensitivity reactions.
CONCLUSION: Patients unreactive to their first PTX infusions, after high-dose and tapering GC premedication, may not require GC prophylaxis for subsequent PTX therapy. Copyright 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886470     DOI: 10.1159/000085618

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  6 in total

1.  Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.

Authors:  Napa Parinyanitikul; Walailuk Tanpipattanakul; Nattaya Poovorawan; Thanapoom Rattananupong; Poranee Laoitthi; Piyada Sithidetphaiboon; Suebpong Thanasanvimon; Virote Sriuranpong
Journal:  Support Care Cancer       Date:  2018-02-12       Impact factor: 3.603

2.  Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy.

Authors:  Ka-Eun Yoo; Rae Young Kang; Ju-Yeun Lee; Yu Jeung Lee; Sung Yun Suh; Kwi Suk Kim; Hyang Sook Kim; Se-Hoon Lee; Byung Koo Lee
Journal:  Support Care Cancer       Date:  2014-12-13       Impact factor: 3.603

3.  Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.

Authors:  Michael J Berger; Craig Vargo; Mary Vincent; Katy Shaver; Gary Phillips; Rachel Layman; Erin Macrae; Ewa Mrozek; Bhuvaneswari Ramaswamy; Robert Wesolowski; Charles L Shapiro; Maryam B Lustberg
Journal:  Support Care Cancer       Date:  2014-12-18       Impact factor: 3.603

4.  Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis.

Authors:  Samuel Dubinsky; Deep Patel; Xiang Wang; Amirrtha Srikanthan; Terry L Ng; Corey Tsang
Journal:  Support Care Cancer       Date:  2022-02-12       Impact factor: 3.603

Review 5.  Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.

Authors:  Matthieu Picard; Mariana C Castells
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

6.  Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.

Authors:  Michael J Berger; Leslie J Dunlea; Amy E Rettig; Maryam B Lustberg; Gary S Phillips; Charles L Shapiro
Journal:  Support Care Cancer       Date:  2011-11-17       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.